Eli Lilly (LLY) Restructuring Costs (2009 - 2026)

Eli Lilly (LLY) has 18 years of Restructuring Costs data on file, last reported at $279.0 million in Q1 2026.

• For the quarter ending Q1 2026, Restructuring Costs rose 697.14% year-over-year to $279.0 million; the trailing twelve-month figure through Mar 2026 stood at $728.0 million (down 18.75% YoY), and the FY2025 full-year result was $484.0 million, down 43.79% from the prior year.
• Restructuring Costs for Q1 2026 stood at $279.0 million, up from $84.1 million in the prior quarter.
• Across five years, Restructuring Costs topped out at $435.0 million in Q2 2024 and bottomed at $35.0 million in Q1 2025.
• The 5-year median for Restructuring Costs is $145.3 million (2022), against an average of $193.7 million.
• The widest annual swing landed in 2025, when Restructuring Costs slumped 75.58%; it then jumped 697.14% in 2026.
• A 5-year view of Restructuring Costs shows it stood at $38.1 million in 2022, then surged by 78.48% to $68.0 million in 2023, then surged by 406.47% to $344.4 million in 2024, then plunged by 75.58% to $84.1 million in 2025, then surged by 231.75% to $279.0 million in 2026.
• The last three Restructuring Costs figures came in at $279.0 million (Q1 2026), $84.1 million (Q4 2025), and $364.9 million (Q3 2025), per Business Quant data.

Peer Comparison